Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Find generic entry opportunities
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Method for treating onychomycosis|
|Abstract:||A novel method for evaluating an effect of an antimicrobial agent which comprises removing the antimicrobial agent remaining in a biological sample or the like to thereby accurately evaluate the effect of the antimicrobial agent without being affected by the remaining antimicrobial agent. A therapeutic agent for onychomycosis which can be obtained according to the evaluation method of the drug effect.|
|Inventor(s):||Tatsumi; Yoshiyuki (Otsu, JP), Yokoo; Mamoru (Otsu, JP), Nakamura; Kosho (Moriyama, JP), Arika; Tadashi (Suita, JP)|
|Assignee:||Kaken Pharmaceutical Co., Ltd. (Bunkyo-ku, Tokyo, JP)|
1. A method for treating a subject having onychomycosis wherein the method comprises topically administering to a nail of said subject having onychomycosis a
therapeutically effective amount of an antifungal compound represented by the following formula: ##STR00003## wherein, Ar is a non-substituted phenyl group or a phenyl group substituted with 1 to 3 substituents selected from a halogen atom and
trifluoromethyl group, R.sup.1 and R.sup.2 are the same or different and are hydrogen atom, C.sub.1-6 alkyl group, a non-substituted aryl group, an aryl group substituted with 1 to 3 substituents selected from a halogen atom, trifluoromethyl group, nitro
group and C.sub.1-16 alkyl group, C.sub.2-8 alkenyl group, C.sub.2-6 alkynyl group, or C.sub.7-12 aralkyl group, m is 2 or 3, n is 1 or 2, X is nitrogen atom or CH, and *1 and *2 mean an asymmetric carbon atom.
2. The method of claim 1, in which the compound represented by the formula (II) is (2R, 3R)-2-(2,4-difluorophenyl)-3-(4-methylen piperidine-1-yl)-1-(1H-1,2,4-triazole-1-yl)butane-2-ol.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.